Aza/pano treatment potentiates subsequent chemotherapy in ALL PDX mouse model. (A) NSG-B2M mice (n = 5 per cohort) transplanted with 1.0 × 10⁶ NTPL-87 cells were treated as depicted. (B) Peripheral blood was monitored for the presence of human CD10⁺ cells to determine change in leukemic percentage over time. (C) Kaplan-Meier survival curves show mice pretreated with AP before DA live significantly longer than mice treated with DA alone (*P < .05). Green and red arrows indicate time when aza/pano or DA treatment began, respectively.